Fig. 1: Baseline characteristics of the cohort (N = 514). | npj Genomic Medicine

Fig. 1: Baseline characteristics of the cohort (N = 514).

From: T-cell priming transcriptomic markers: implications of immunome heterogeneity for precision immunotherapy

Fig. 1

a Pie chart of cancer types in the cohort (N = 514). Others include: cervical cancer (N = 5), bladder cancer (N = 4), gallbladder and extrahepatic bile duct cancers (N = 4), prostate cancer (N = 4), brain and nervous system cancers (N = 3), kidney and renal pelvis cancers (N = 3), squamous cell carcinoma of the skin (N = 3), thyroid cancer (N = 3), adrenal gland cancer (N = 3), lipomatous neoplasm (N = 2), mesothelioma (N = 2), basal cell carcinoma of the skin (N = 1), ocular melanoma (N = 1), primary peritoneal carcinoma (N = 1), and thymic cancer (N = 1). b Frequency of patients with high expression of T cell priming markers (N = 514). Horizontal axis represents the percentage of patients with high expression of each T cell priming marker. Transcript abundance was normalized to internal housekeeping gene profiles and ranked (0–100) to standardized values by comparing to a reference population of 735 tumors spanning 35 histologies. The expression profiles were stratified by rank values into “Low” (0–24), “Intermediate” (25–74), and “High” (75–100). See Methods as well.

Back to article page